Kangfang Biologics announced Ivonescimab combined with Ligufalimab as a first-line treatment for PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma at ESMO 2024

Head-to-head Section 3 trial evaluating pembrolizumab has begun

Hongkong, September 15, 2024 /PRNewswire/ — 2024 European Society for Medical Oncology (ESMO) Convention, it is coming Launched section 2 medical outcomes of its independently developed PD-1/VEGF bispecific antibody ivonescimab with or with out ligufalimab (anti-CD47 antibody AK117) for the first-line remedy of PD-L1-positive (CPS ≥ 1) relapse or metastatic head and neck squamous cell illness Most cancers (R/M HNSCC)

As of knowledge cutoff date March 19, 2024The outcomes point out that for HNSCC the place speedy tumor shrinkage is extremely fascinating, the ivonescimab routine has demonstrated clinically significant reductions in tumor measurement. When mixed with ligufalimab, each tumor shrinkage and survival advantages have been additional improved in comparison with ivonescimab alone. Preliminary efficacy knowledge have been obtained utilizing ivonescimab alone and together with ivonescimab plus ligufalimab, exceeding beforehand disclosed PD-1 research.

• The target response charge (ORR) was 30% within the ivonescimab monotherapy arm, whereas the ORR elevated to 60% within the ivonescimab plus ligufalimab arm. The illness management charge (DCR) was 80% within the ivonescimab monotherapy arm and improved to 90% within the ligufalimab arm. As of the time of the report, the anti-tumor efficacy of ivonescimab continues to be encouraging, with some sufferers demonstrating enchancment from steady illness (SD) to partial response (PR). The ORRs for ivonescimab monotherapy and ivonescimab plus ligufalimab have been 40% and 65%, respectively.
• Median progression-free survival (mPFS) within the ivonescimab monotherapy arm was 5.0 months, however the 6-month PFS charge was not but reached. The median progression-free survival (mPFS) of the mixed ligfarimab group was 7.1 months, and the 6-month progression-free survival charge was 71.8%.
• The protection profile of ivonescimab for first-line remedy of PD-L1-positive R/M HNSCC was manageable, with no treatment-related hostile occasions (TRAEs) resulting in drug discontinuation or dying in each the ivonescimab monotherapy and ivonescimab plus ligufalimab teams.

Though programmed cell dying protein 1 (PD-1) inhibitors mixed with chemotherapy are authorised as first-line remedy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), some sufferers don’t reply nicely to this method. The necessity for brand new remedy methods is highlighted. it is coming A section 3 medical research has been initiated to check ivonescimab plus ligufalimab with pembrolizumab within the first-line remedy of PD-L1-positive R/M HNSCC. This analysis has the potential to supply these sufferers with a brand new, extremely efficient immunotherapy possibility and should pave the way in which for developments in Most cancers Immunotherapy 2.0.